ALPN:NSD-Alpine Immune Sciences Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 7.8

Change

-57.17 (-87.99)%

Market Cap

USD 4.46B

Volume

20.00

Analyst Target

USD 21.50
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-21 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+1.70 (+0.35%)

USD 124.65B
REGN Regeneron Pharmaceuticals Inc

+9.97 (+0.97%)

USD 110.51B
MRNA Moderna Inc

-5.20 (-3.58%)

USD 57.87B
BNTX BioNTech SE

-3.92 (-4.08%)

USD 24.18B
ARGX argenx NV ADR

-1.34 (-0.35%)

USD 23.09B
ALNY Alnylam Pharmaceuticals Inc

+0.34 (+0.21%)

USD 20.25B
GMAB Genmab AS

-0.22 (-0.83%)

USD 18.17B
BGNE BeiGene Ltd

-3.80 (-2.28%)

USD 17.74B
RPRX Royalty Pharma Plc

-0.28 (-1.03%)

USD 16.18B
BMRN Biomarin Pharmaceutical Inc

-0.73 (-0.87%)

USD 15.32B

ETFs Containing ALPN

CURE:AU ETFS S&P Biotech ETF 1.86 % 0.00 %

-0.71 (-1.46%)

USD 0.04B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -59.08% 11% F 7% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return -59.08% 11% F 7% C-
Trailing 12 Months  
Capital Gain -25.78% 51% F 30% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -25.78% 51% F 30% F
Trailing 5 Years  
Capital Gain 37.32% 77% C+ 69% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 37.32% 77% C+ 66% D+
Average Annual (5 Year Horizon)  
Capital Gain 101.35% 92% A 95% A
Dividend Return 101.35% 92% A 95% A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 170.48% 14% F 9% A-
Risk Adjusted Return 59.45% 96% N/A 85% B
Market Capitalization 4.46B 95% A 88% B+

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.